- October 24, 2025 - Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at #ObesityWeek2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m
Metabolic features of the cell danger response
Sequencing data were retrieved from the European Bioinformatics Institute (accession number: ERP120131)
The second most important mental disease is schizophrenia in which case The Global Burden of Disease 2000 estimates 1.1 % of all DALY and 2.8 % of the total YLD (Saraceno 2002)
Factors such as diet, physical activity, sleep quality, underlying medical conditions, other medications, and individual metabolism can all influence both side effects and overall results